Navigation Links
VTT searches for novel biomarkers and targets for preventing or treating Type 2 diabetes
Date:2/21/2012

VTT is participating in two new European projects focusing on type 2 diabetes. The projects aim at identifying new therapeutic choices and strategies for preventing the disease. Focus is on obtaining information on cellular dysfunction in diabetes and the effects of changes in lifestyle. The goal includes planning individual lifestyle instructions for people at high risk of diabetes and exploiting the results in a major European health insurance system.

The EU BetaBAT project aims at developing individual therapeutic choices for type 2 diabetics by identifying the connection between the genome and individual cell-level changes causing the disease. The scientists will use systems biological tools to boost the capacity of beta cells and brown adipocytes for regaining homeostatic control.

The other EU project, DEXLIFE, aims at disease prevention by identifying novel diagnostic and predictive biomarkers to detect the progression toward type 2 diabetes in individuals at high risk of the disease. Large-scale data will be acquired during the project, including information on genes and metabolites. The intervention aiming at type 2 diabetes prevention will be set up in the real-life context of a major European health insurance system.

In both projects VTT leads the work packages on integration and modelling of data. VTT has a central role in applying systems biology strategies including metabolomics, integrative bioinformatics and biosystems modelling to identify putative organelle-specific targets (BetaBAT) and early predictive markers of type 2 diabetes progression (DEXLIFE).

The global prevalence of diabetes has reached 285 million and is projected to rise to 435 million by 2030. Type 2 diabetes is preventable by sustained changes in diet and physical exercise. Despite this, modern societies are already approaching 10% population prevalence of diabetes, and another 15% with pre-diabetes. The costs of type 2 diabetes are huge, approaching 10% of all health costs.


'/>"/>

Contact: Matej Oresic
matej.oresic@vtt.fi
358-207-224-491
VTT Technical Research Centre of Finland
Source:Eurekalert

Related biology news :

1. UK robot sub searches for signs of melting 60 km into an Antarctic ice shelf cavity
2. Trauma drama: K-State professor researches drama queen of immune system
3. A Spanish botanist searches for prehistoric flora refuges in China
4. AZTI-Tecnalia researches the use of vegetable by-products for animal feed
5. Scientists identify novel inhibitor of human microRNA
6. Conaway Lab identifies novel mechanism for regulation of gene expression
7. LIAI launches new division to look at novel approaches to heart disease and inflammation
8. Childrens National researchers develop novel anti-tumor vaccine
9. Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer
10. Novel publishing approach puts textbook in more hands
11. GEN reports on novel tools for deciphering biological networks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology: